🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "major milestone" in the battle against increasingly resistant strains of the infection, according to scientists.

An International Challenge

Gonorrhoea infections are on the rise around the world, with estimates suggesting more than 82 million instances per year. Particularly high rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of increasing worldwide cases, escalating drug resistance and the very limited available drugs currently available.”

Public health authorities are particularly alarmed about the rise in antibiotic-resistant strains. The World Health Organization has listed it as a "high-priority threat". A tracking program revealed that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Receive Clearance

One new antibiotic, alternatively called Nuzolvence, was cleared by the US FDA in December for use against gonorrhoea. This disease can lead to serious health problems, including infertility. Researchers believe that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, created by the drugmaker GSK, also received approval in close succession. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a unique collaborative effort for antibiotic development. The charitable organization GARDP worked alongside the pharmaceutical company Innoviva to see it through.

“This milestone marks a significant shift in the therapy of superbug gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Clinical Trial Outcomes and Global Access

Based on findings published in a major medical journal, the new drug eradicated the vast majority of cases of the STI. This establishes an comparable level with the typical regimen, which uses an injection and a pill. The study included nearly 1,000 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the rights to register and commercialise the drug in numerous low-income and middle-income countries.

Doctors treating patients have expressed positive views. Having a easy-to-administer therapy of this kind is described as a "critical tool" for gonorrhoea control. This is considered vital to alleviate the strain of the disease for individuals and to prevent the spread of untreatable gonorrhoea around the world.